141995-50-8

Basic information

• Product Name: Guanidine, N-[3-(1H-imidazol-4-yl)propyl]-N'-[2-[[[1-(phenylmethyl)-1H-imidazol-2-yl ]methyl]thio]ethyl]-, monohydrochloride
• CAS NO: 141995-50-8
• Molecular Formula: C20H27N7S.ClH
• Molecular Weight: 506.93
• Mol File: 141995-50-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Guanidine, N-[3-(1H-imidazol-4-yl)propyl]-N'-[2-[[[1-(phenylmethyl)-1H-imidazol-2-yl ]methyl]thio]ethyl]-, monohydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Guanidine, N-[3-(1H-imidazol-4-yl)propyl]-N'-[2-[[[1-(phenylmethyl)-1H-imidazol-2-yl ]methyl]thio]ethyl]-, monohydrochloride(141995-50-8)
• EPA Substance Registry System: Guanidine, N-[3-(1H-imidazol-4-yl)propyl]-N'-[2-[[[1-(phenylmethyl)-1H-imidazol-2-yl ]methyl]thio]ethyl]-, monohydrochloride(141995-50-8)

Safety Data

• Hazardous Substances Data: 141995-50-8(Hazardous Substances Data)

Upstream product

• 33550-98-0 N-[3-(1⁽³⁾H-imidazol-4-yl)-propyl]-phthalimide 
• 141995-51-9 2-<<(1-benzylimidazol-2-yl)methyl>thio>ethanamine dihydrochloride 
• 40546-33-6 3-[imidazol-4⁽⁵⁾-yl]propylamine 
• 5376-10-3 1-benzyl-2-(hydroxymethyl)imidazole 
• 141995-60-0 N-Benzoyl-N'-[2-(1-benzyl-1H-imidazol-2-ylmethylsulfanyl)-ethyl]-N''-[3-(1H-imidazol-4-yl)-propyl]-guanidine 

Relevant articles and documents

Synthesis and histamine H2-receptor activity of heterocyclic impromidine analogues.

Analogues of the H2-agonist impromidine with unsubstituted or substituted aromatic or non-aromatic heterocycles instead of the 5-methylimidazole group were prepared via the benzoylguanidine method and tested for H2-agonistic and H1-antagonistic activity in the guinea-pig isolated right atrium and ileum, respectively. Compounds with unsubstituted 2- or 3-pyridyl, 2-pyrazinyl, or 5-pyrimidyl thioether portion proved to be about equipotent in the atrium (about 2-4x histamine). Highest potency was found in the 5-chloro-3-pyridylthioethylguanidine 8h, that is about 20 times more potent as an H2-agonist than histamine, corresponding to about 8 times the activity of the unsubstituted parent compound 8g. It is demonstrated by the piperidinyl- and morpholinylalkyl guanidines 8m-o that an aromatic ring is not required in the affinity-conferring moiety of H2-agonists (8n: 1.3x histamine). Replacement of the (5-methylimidazol-4-yl)methylthio group in the H2-antagonist cimetidine by halogenated pyridyl, pyrazinyl and pyrimidinyl thioethers resulted in compounds inactive as H2-antagonists, giving further evidence for differences in the structural requirements of the affinity-conferring portions of H2-agonists and antagonists and their mode of interaction with the receptor protein.